A-836,339, a product of Abbott Laboratories, is a potent full agonist of the cannabinoid receptor. Notably, it exhibits selectivity for CB2, with Ki values of 0.64 nM at CB2 compared to 270 nM at the psychoactive CB1 receptor. At lower doses, A-836,339 displays selective analgesic, anti-inflammatory, and anti-hyperalgesic effects. However, its high efficacy at both CB1 and CB2 receptors leads to the emergence of cannabis-like effects at higher doses despite its lower binding affinity for CB1. In 2012, A-836,339 was identified using X-ray crystallography in a substance described as a “dubious product” being sold in Japan. Although the product was a white powder rather than herbal incense, it was suggested to be intended for human consumption.
|CompTox Dashboard (EPA)||DTXSID601010006|
|Chemical and physical data|
|Molar mass||310.46 g·mol−1|
1. What is A-836,339?
A-836,339 is a synthetic drug developed by Abbott Laboratories known for its potent action as a cannabinoid receptor full agonist.
2. How does A-836,339 interact with cannabinoid receptors?
A-836,339 exhibits selectivity for the CB2 receptor, with a significantly higher affinity for CB2 than the psychoactive CB1 receptor. Its actions are dose-dependent.
3. What are the primary effects of A-836,339 at low doses?
At lower doses, A-836,339 produces selective analgesic, anti-inflammatory, and anti-hyperalgesic effects, which can benefit therapeutic purposes.
4. Are there any notable effects at higher doses?
Yes, at higher doses, A-836,339 can produce typical cannabis-like effects. This is despite its relatively low binding affinity for the CB1 receptor.
5. Has A-836,339 been associated with any regulatory concerns?
In 2012, A-836,339 was identified as a “dubious product” sold in Japan, even though the product was in the form of a white powder, not herbal incense. This raised concerns about its potential for human consumption.
6. Is A-836,339 legally available for use or purchase?
The legal status of A-836,339 may vary by region. It’s crucial to know local regulations and restrictions regarding its use and availability.
7. Are there any ongoing studies or research related to A-836,339?
Research in the field of synthetic cannabinoids is continuously evolving. To stay updated on the latest findings, consult scientific literature and authoritative sources.
8. What precautions should be taken when dealing with substances like A-836,339?
Due to potential health risks and legal considerations, it’s advisable to exercise caution and seek guidance from healthcare professionals and regulatory agencies when dealing with substances like A-836,339.
- Delve into a study by McGaraughty S et al. from February 2009, which explores how a CB2 receptor agonist, A-836339, affects wide dynamic range neuronal activity in neuropathic rats. Learn about the contributions of both spinal and peripheral CB2 receptors in this context.
- Gain insights from the research conducted by Yao BB and team in January 2009, characterizing A-836339, a selective cannabinoid CB2 receptor agonist. This research involves in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging, offering a comprehensive understanding of this compound’s properties.
- Discover a study by Uemura N et al. from 2013, which identifies the synthetic cannabinoid A-836339 as a novel compound found in a specific product. This research sheds light on the presence of A-836339 in a real-world context.